Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ARSD, a novel ERα downstream target gene, inhibits proliferation and migration of breast cancer cells via activating Hippo/YAP pathway.

Cell death & disease - 2 Nov 2021

Lin Yun, Li Chun, Xiong Wei, Fan Liping, Pan Hongchao, Li Yaochen

Abstract excerpt

Advanced breast cancer (BC), especially basal like triple-negative BC (TNBC), is a highly malignant tumor without viable treatment option, highlighting the urgent need to seek novel therapeutic targets. Arylsulfatase D (ARSD), localized at Xp22.3, is a female-biased gene due to its escaping from X chromosome inactivation (XCI). Unfortunately, no systematic investigation of ARSD on BC has been reported. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arylsulfatases
Share to Chromosomes, Human, X

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to Hippo Signaling Pathway

Share to RNA, Long Noncoding

Share to Triple Negative Breast Neoplasms

Share to X Chromosome Inactivation

Share to YAP-Signaling Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 34725332
DOI: 10.1038/s41419-021-04338-8
PMCID: PMC8560752

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ARSD, a novel ERα downstream target gene, inhibits proliferation and migration of breast cancer cells via activating Hippo/YAP pathway.PMID 34725332Read ↗

Single-Cell Transcriptional and Epigenetic Profiles of Male Breast Cancer Nominate Salient Cancer-Specific EnhancersSemantic proximity Read ↗

An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen.Semantic proximity Read ↗

MYSM1 co-activates ERα action via histone and non-histone deubiquitination to confer antiestrogen resistance in breast cancerSemantic proximity Read ↗

Super-enhancer-hijacking RBBP7 potentiates metastasis and stemness of breast cancer via recruiting NuRD complex subunit LSD1Semantic proximity Read ↗

Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profilingSemantic proximity Read ↗

<i>SERPINA1</i>is a direct estrogen receptor target gene and a predictor of survival in breast cancer patientsSemantic proximity Read ↗

Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancerSemantic proximity Read ↗

Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancerSemantic proximity Read ↗

Global Gene Repression by the Steroid Receptor Coactivator SRC-1 Promotes OncogenesisSemantic proximity Read ↗

The estrogen receptor/GATA3/FOXA1 transcriptional network: lessons learned from breast cancerSemantic proximity Read ↗

Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progressionSemantic proximity Read ↗

Estrogen Receptor Signaling in Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.